文献速递糖尿病性腺与生殖内分泌

度拉糖肽对2型糖尿病男性勃起功能的影响:REWIND试验探索性分析

Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2021-06-18

REWIND试验的探索性分析纳入3725名50岁以上2型糖尿病男性,比较度拉糖肽与安慰剂对勃起功能障碍的影响。长期使用度拉糖肽可能减少2型糖尿病男性中度或重度勃起功能障碍的发生。

要点

  • 长期使用度拉糖肽可能降低2型糖尿病男性中度或重度勃起功能障碍风险。

核心结论

  • 长期使用度拉糖肽可能减少2型糖尿病男性中度或重度勃起功能障碍的发生。

研究设计与样本

  • REWIND试验为双盲、安慰剂对照随机试验,在24个国家371个中心进行。
  • 纳入5312名50岁以上2型糖尿病男性,其中3725名完成基线及至少一次随访IIEF问卷并纳入分析。
  • 参与者按1:1随机接受度拉糖肽或安慰剂。

临床怎么用

  • 对于2型糖尿病男性,度拉糖肽治疗可能有助于降低中度或重度勃起功能障碍的发生风险。

局限性

  • 该分析为探索性分析,结果需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diabetes is a major risk factor for erectile dysfunction, however, the effect of GLP-1 receptor agonists on erectile dysfunction is unknown. We aimed to assess the incidence, prevalence, and progression of erectile dysfunction in men treated with dulaglutide compared with placebo, and to determine whether dulaglutide's effect on erectile dysfunction was consistent with its effect on other diabetes-related outcomes. METHODS: The Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial was a double-blind, placebo-controlled randomised trial of the effect of dulaglutide on cardiovascular outcomes. REWIND was done at 371 sites in 24 countries. Men and women aged older than 50 years with type 2 diabetes, who had either a previous cardiovascular event or cardiovascular risk factors, were randomly assigned (1:1) to receive either dulaglutide or placebo. Participating men were offered the opportunity to complete the standardised International Index of Erectile Function (IIEF) questionnaire at baseline, 2 years, 5 years, and study end. We did an exploratory analysis, in which we included participants who completed a baseline and at least 1 follow-up IIEF questionnaire. The primary outcome for these analyses was the first occurrence of moderate or severe erectile dysfunction following randomisation, assessed by the erectile function subscores on IIEF. This analysis was part of the REWIND trial, which is registered with ClinicalTrials.gov, NCT01394952. FINDINGS: Between Aug 18, 2011, and Aug 14, 2013, 3725 (70·1%) of 5312 male participants with a mean age of 65·5 years (SD 6·4 years) were analysed, of whom 1487 (39·9%) had a history of cardiovascular disease, and 2104 (56·5%) had moderate or severe erectile dysfunction at baseline. The incidence of erectile dysfunction following randomisation was 21·3 per 100 person-years in the dulaglutide group and 22·0 per 100 person-years in the placebo group (HR 0·92, 95% CI 0·85-0·99, p=0·021). Men in the dulaglutide group also had a lesser fall in erectile function subscore compared with the placebo group, with a least square mean difference of 0·61 (95% CI 0·18-1·05, p=0·006). INTERPRETATION: Long-term use of dulaglutide might reduce the incidence of moderate or severe erectile dysfunction in men with type 2 diabetes. FUNDING: Eli Lilly and Company.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Bajaj HS, Gerstein HC, Rao-Melacini P, et al. Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial. Lancet Diabetes Endocrinol. 2021. PMID: 34153269. doi:10.1016/S2213-8587(21)00115-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。